A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-Beta-1a for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis.

Trial Profile

A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-Beta-1a for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Interferon beta-1a; Methylprednisolone
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MECOMBIN
  • Sponsors Biogen Idec
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Mar 2012 Planned number of patients changed from 345 to 400 as reported by ISRCTN: Current Controlled Trials.
    • 01 Jul 2010 Results published in Lancet Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top